Form 8-K - Current report:
SEC Accession No. 0001193125-25-117878
Filing Date
2025-05-12
Accepted
2025-05-12 17:00:19
Documents
13
Period of Report
2025-05-12
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K d866380d8k.htm   iXBRL 8-K 23326
  Complete submission text file 0001193125-25-117878.txt   144512

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA kalv-20250512.xsd EX-101.SCH 2854
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE kalv-20250512_lab.xml EX-101.LAB 17995
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE kalv-20250512_pre.xml EX-101.PRE 11264
15 EXTRACTED XBRL INSTANCE DOCUMENT d866380d8k_htm.xml XML 3648
Mailing Address 55 CAMBRIDGE PARKWAY SUITE 901E CAMBRIDGE MA 02142
Business Address 55 CAMBRIDGE PARKWAY SUITE 901E CAMBRIDGE MA 02142 (857) 999-0075
KalVista Pharmaceuticals, Inc. (Filer) CIK: 0001348911 (see all company filings)

EIN.: 200915291 | State of Incorp.: DE | Fiscal Year End: 0430
Type: 8-K | Act: 34 | File No.: 001-36830 | Film No.: 25935825
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)